Oculis will attend be attending the Jefferies 2016 London Healthcare Conference. The conference takes place on November 16-17, 2016.
Dr. Einar Stefansson, Oculis’ co-founder, will make a presentation at Cambridge Healthtech Institute’s fourth annual Targeting Ocular Disorders conference. The conference takes place on September 21-22, 2016 in Boston, MA. Dr. Stefansson’s presentation, titled “Nanoparticle Eye-Drops Deliver Drugs to Retina in Human Patients” will discuss Oculis’ solubilizing nanoparticle (SNP) eye drop technology and is scheduled on September 20 at 3.15 PM under the section on innovative drug delivery methods for ocular disorders.
Oculis announced today the close of a Series A financing round, led by Brunnur Ventures and Silfurberg. The new capital will support continued development of the company’s patented solubilizing nanoparticle (SNP) drug delivery platform and the company’s drug candidates, including the first topical eye-drops for treatment of diabetic macular edema.
Prof. Einar Stefansson, Oculis’ chairman and co-founder, gave a honorary key note lecture at The Nordic Ophthalmology Congress in Denmark June 8-12, 2016 and received the biennial gold medal for his contribution to eye research. The lecture included Oculis’ break through nanotechnology that delivers drug molecules in eye drops to the back of the eye and offers noninvasive drug therapy for retinal diseases.
Prof. Thorsteinn Loftsson, Oculis’ co-founder and Chief Scientific Officer, is on the recently published Thomson Reuters’ list of The World’s Most Influential Scientific Minds for 2015. This is the second year in a row Prof. Loftsson is included on Thomas Reuters’ list of leading researchers.
REYKJAVÍK, ICELAND, 16 DECEMBER, 2015 – Oculis’ breakthrough technology allows for the first time drug treatment of retinal diseases with topical eye drops, reducing the need for intravitreal injections and implants, which are the current standard of care. Retina delivery with the Oculis’ eye drops has been demonstrated in two phase II studies in DME […]
Oculis will attend be attending the 8th Annual Conference Biotech Showcase 2016 in San Francisco, CA. The conference takes place on January 11-13, 2016.
Oculis has been awarded a research grant from the Technology Development Fund.
Oculis today completed the formation of a new Scientific and Medical Advisory Board. The Advisory Board consists of five members with vast experience from ophthalmology and the pharmaceutical industry.
A new article has recently been published on the efficacy and safety of DexNP eye drops in DME patients, demonstrating that use of DexNP significantly improves visual acuity and decreases macular thickness in patients with DME.